Research and Markets: Alkermes's ALKS-5461 (Major Depressive Disorder) Drug Report - Forecast and Market Analysis to 2023
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/q94b6t/alks5461_major) has announced the addition of the "ALKS-5461 (Major Depressive Disorder) - Forecast and Market Analysis to 2023" report to their offering.
“ALKS-5461 (Major Depressive Disorder) - Forecast and Market Analysis to 2023”
ALKS-5461 is being developed by Alkermes as an adjunctive treatment for MDD in patients who have had an inadequate response to standard therapies. According to Alkermes, ALKS-5461 is expected to enter Phase III development during the first half of 2014. Following its very successful Phase II trial, the FDA granted Fast Track status for ALKS-5461 in order to facilitate its development and expedite its review by the regulatory authority (Alkermes, press release, October 10, 2013).
- Overview of Major depressive disorder, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on ALKS-5461 including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for ALKS-5461 for the top eight countries from 2013 to 2023.
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan and Australia.
Key Topics Covered:
1 Tables & Figures
3 Disease Overview
4 Disease Management
5 Competitive Assessment
6 Unmet Needs and Opportunities
7 Pipeline Assessment
For more information visit http://www.researchandmarkets.com/research/q94b6t/alks5461_major